Cancer therapies which are less toxic and invasive than their existing counterparts are highly desirable. The use of RF electric-fields that penetrate deep into the body, causing minimal toxicity, are currently being studied as a viable means of non-invasive cancer therapy. It is envisioned that the interactions of RF energy with internalized nanoparticles (NPs) can liberate heat which can then cause overheating (hyperthermia) of the cell, ultimately ending in cell necrosis.
Introduction
The absorption of RF energy by biological tissue (due to their inherent electrical permittivity) results in elevated tissue temperatures as a function of time, which eventually leads to cell death by hyperthermia. It is hypothesized that cancer hyperthermia can be optimized through the use of targeted nanomaterials that internalize within the cancer cell and act as RF-thermal transducers, leaving the neighboring healthy, normal cells intact. Several reports have already shown that a variety of NPs can act as effective RF heat sources which aid in cancer necrosis [1] [2] [3] [4] . In these regards, gold NPs (AuNPs) [3] [4] [5] , carbon nanotubes 1 , and quantum dots 6, 7 have exhibited exciting characteristics when used in both in vitro and in vivo RF experiments. Although the exact nature of the heating mechanism of these NPs when exposed to an RF-field is still being debated, a series of fundamental experiments using AuNPs has placed great significance on both NP size and aggregation states. It was shown that only AuNPs with diameters <10 nm will heat when exposed to an RF-field
Assessing RF Heating of NP Colloids: AuNPs as an Example
1. In general, for each NP sample being investigated, first wash the sample several times through a centrifugation filter with deionized (DI) water to remove background ions and contaminants. All ions and contaminants will have been removed from the AuNP suspension when the liquid being washed out has similar RF heating rates (HRs) as DI water. This purification process also allows for higher concentrations of NPs to be obtained. It is worth noting that although using AuNPs in this example, the fundamental principles can be applied to other NP materials. 2. As an example, purify a 500 ml bottle of commercially available AuNPs of diameter 5 nm and then subject them to a 13.56 MHz RF field of electric-field strength 90 kV/m. 1. Take ~125 ml from the stock AuNP solution and split between six 50 kDa centrifuge filter tubes. Centrifuge at 3,000 rpm. for 2 min 5 sec. Remove filtered buffer and refill filters with more stock solution. Repeat until all 500 ml has been filtered. 2. Replace the filtered buffer with a similar volume of DI water and repeat approximately 8 times (or until the filtered buffer RF HRs are equivalent to DI water). Note, UV-Vis analysis can also be used to monitor contaminant absorption peaks. Once the buffer contaminants have been fully removed, pipette approximately 0.5 ml DI water into each filter and resuspend the AuNPs by repeated pipetting. This should completely remove the AuNPs from the filter and allow for full resuspension. Combine all six suspensions into one 15 ml Eppendorf tube. 3. Once the AuNPs have been purified and concentrated, analyze the sample using ICP-OES and/or ICP-MS, UV-vis and Zeta potential for data on concentration and NP stability, respectively. SEM and/or TEM analysis can also be used to obtain morphological data. Detailed sample preparation for these techniques can be found in the literature 4 .
3. Using the Kanzius RF system described in previous studies 8 , or derivations of this system, place a 1.3 ml cylindrical quartz cuvette so that the RF electric-field in air (with no sample present) would be ~90 kV/m inside the cuvette. For a standard saline sample (0.9 % NaCl) the electric-field would be reduced to ~1.1 kV/m. These are the approximate conditions used to allow comparisons to be made between different systems.
1. Pipette 1.3 ml of a 1,000 mg/l sample of purified AuNP colloid into the quartz cuvette and introduce this into the RF-field. This can be done by using a custom-built Teflon sample holder. Expose sample to the RF-field for a period of 120 sec or until the sample reaches 70 °C to prevent electrical arcing or rapid boiling. Capture the thermal imaging data (as well as control areas) using an IR camera & associated software. Repeat this procedure three times. 2. Filter the sample through another 50 kDa centrifuge filter to extract the AuNPs from the DI water buffer. Re-expose the buffer to the RF-field, again three times. The difference in HRs between the AuNP colloid and the background DI water buffer determines the HR due to the AuNPs themselves. Expect to obtain HRs of ~0.3 °C/sec and 0.05 °C/sec to give an AuNP dependent HR of ~ 0.25 °C/sec. Resuspend the remaining AuNPs from the filter in 1.3 ml water for in vitro/vivo experiments.
Nanoparticle-assisted RF-induced Hyperthermia: In vitro Studies
1. These in vitro studies can be applied to any type of cancer cell type that form 2D monolayers. In this experiment use human hepatocellular carcinoma derived Hep3B cells. 1. Plate ~50,000 cells in the front three wells of a 12-well plate with 1 ml of growth media. Repeat this 6 times (use three plates for NP studies and three plates as controls). Incubate at 37.5 °C for 24 hr before introducing the NPs. Sterilize NPs first using BioSafety Cabinet UV-light exposure for 5 min. 2. Into each well introduce 0.1 ml of a 1,000 mg/L AuNP solution and leave for another 24 hr. Add 0.1 ml of water into each well of the three control cell plates and also leave for 24 hr. 3. After 24 hr have passed, aspirate the cell media and wash with PBS to remove any surface-bound AuNPs. Replace the cell media.
Cells are now ready for RF exposure.
2. Place each 12-well cell pack within the RF-field. Wait until the cells have cooled to 31 °C. Turn on the RF generator and expose for 3.5 min. The final temperature of the cell media will be ~37 °C. Turn off the RF field. Remove the cells and place them in an incubator for 24 hr before analysis. 1. Remove cells from the incubator and aspirate cell media. Add 1.6 ml of cell media to each well as well at 0.4 ml of MTT reagent. Incubate cells for 4 hr. Aspirate media and replace with 2 ml of Dimethyl sulfoxide (DMSO). Place the cell plates on a bench rocker and leave for 10 min to allow the DMSO to solubilize the MTT reagents. Finally, pipette 100 μl of each well into a 96-well plate and optically read the well at 570 nm using a plate reader such as the SPECTROstar Nano plate reader. 
Nanoparticle-assisted RF-induced Hyperthermia: In vivo Studies

Discussion
These protocols allow the experimentalist to fully analyze the extent to which nanomaterials (in this case AuNPs) can increase RF-induced hyperthermia for cancer treatment. The first protocol specifically deals with analyzing heat production from highly-concentrated and purified AuNP samples. Although other groups have reported heat production primarily from the buffers which the AuNPs are suspended in and not the AuNPs themselves [9] [10] [11] , their RF systems used lower concentrations of AuNPs with diameters >10 nm, as well as lower RF operating powers with electric-field strengths <90 kV/m which are too low to see any noticeable RF heating effects from AuNPs. Only by following the protocols and parameters listed in this report can the experimentalist observe the nanoscale heat phenomenon.
The in vitro section allows development of cellular-RF-NP interfaces to be studied for optimized RF/NP-induced hyperthermia. Before addition of AuNPs and RF exposure, you should expect to have a viable 2D layer growth of the relevant cancer cell lines (in this case Hep3B). However, the correct RF exposure time for each cell line needs to be predetermined before these experiments by exposing cells to the RF field at different time points e.g. 2 -8 min) and looking at their viability profile after 24 hr. The correct RF exposure time to use should be where the cells are ~80% viable. In the case of Hep3B cells this was found to be ~3.5 min.
The simplest assay of choice for viability is the standard 3-(4,5-dimethylthiazol2-yl)-2.5-diphenyltetrazolium bromide (MTT) assay, although another assay may be needed if it is anticipated that the NPs will interact with the assay reagents (as was the case with MTT assay reacting with CNTs 13 ). Other more advanced and detailed assays can be used to assess cell death mechanism such as FACS analysis with Annexin-V and propidium iodide (PI) staining. Future in vitro system developments within our group will look at placing the cells in a temperature-controlled RF-inert incubator to completely rule out any possible sources of hyperthermia due to bulk heating of the cell media. Also, the amount of AuNPs which need to be internalized within a cell for maximum cell death, as well as their stability within intracellular organelles, will be investigated in greater detail. This is in accordance with recent work which showed that AuNPs must be non-aggregated within lysosomes for enhanced RFtherapy 4 .
Finally, in vivo protocols were described to allow for full bio-analysis of AuNPs in ectopic hepatic cancer mice models for their ability to control or decrease tumor growth and/or size in combination with RF therapy. An important point for discussion is the ability for the RF-field to induce skin burns on the mouse due to incorrect grounding procedures. The use of properly grounded and placed copper tape, as mentioned in the protocol section, is a requirement in order to stop these burns.
Future in vivo work in our lab will work on assessing the actual mechanism of tumor death/size control from RF-AuNP exposure. Although it is hypothesized that hyperthermia plays a critical role, this has to be validated though the use of such controls as direct insertion of opticalfiber thermal probes into the tumor and surrounding healthy cells to look at the RF-induced temperature response of such tissues. Also, the development of an intracellular fluorescent thermal dye whose emission wavelength is a direct function of temperature would be an excellent tool for this validation and could also be used for in vitro models.
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